Journal of Theoretical BiologySynthetic BiologyPeer-reviewed journal article
Optimal control of acute myeloid leukaemia
Jesse A. SharpiD, Alexander P. BrowningiD, Tarunendu MapderiD, Kevin BurrageiD, Matthew J. SimpsoniD
Abstract
Acute myeloid leukaemia (AML) is a blood cancer affecting the haematopoietic stem cells of the myeloid cell line. AML is routinely treated with chemotherapy, and so it is of great interest to develop optimal chemotherapy treatment strategies. In this work, we incorporate an immune response into a stem cell model of AML, since we find that previous models lacking an immune response are inappropriate for deriving optimal control strategies. Using optimal control theory, we produce continuous controls and bang-bang controls, corresponding to a range of objectives and parameter choices. Through example calculations, we provide a practical approach to applying optimal control using Pontryagins maximum principle. In particular, we describe and explore factors that have a profound influence on numerical convergence. We find that the convergence behaviour is sensitive to the method of control updating, the nature of the control, and to the relative weighting of terms in the objective function. All codes we use to implement optimal control are made available.
- Citations
- 39
- FWCI
- 2.27
- Field percentile
- top 12%
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Designing combination therapies using multiple optimal controls
Jesse A. Sharp, Alexander P. Browning, … Matthew J. Simpson·Journal of Theoretical BiologyPeer-reviewed·Jul 1, 2020
- Optimal control of Multiple Myeloma assuming drug evasion and off-target effects
James Lefevre, Brodie Lawson, … Kevin Burrage·bioRxiv·Jun 6, 2024
- Cytokine response of acute myeloid leukemia cells has impact on patient prognosis: Insights from mathematical modeling
T. Stiehl, A. D. Ho, A. Marciniak-Czochra·bioRxiv·Nov 26, 2017
- Oncogenic drivers dictate immune control of acute myeloid leukemia.
R. J. Austin, J. Straube, … M. J. Bywater·bioRxiv·Feb 8, 2023
- Use of CD122+ natural killer cell precursors for superior anti-leukemia responses.
S. Guglietta, L. Cardenas, C. Krieg·bioRxiv·Oct 24, 2022
- Tetraspanin CD81 promotes leukemia stem cell function and represents a new therapeutic vulnerability in acute myeloid leukemia
F. Gonzales, P. Peyrouze, … M. CHEOK·bioRxiv·Sep 20, 2023